23 matches for your search in the start-up spotlight
rss
"It’s time for true automation–connecting and fully automating all processes in the modern biology lab and making the dream of walk-away capabilities a reality”
08-May-2025
Trilobio, the Company building the fully automated robotic lab-in-a-box for biologists, announced it has raised $8 million USD Seed investment. The oversubscribed round was led by Initialized Capital, including participation from Argon Ventures and Lowercarbon Capital. Trilobio was founded in ...
Seed funding to accelerate the development of a pipeline for targeted protein degradation
12-Mar-2025
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, announced the closing of its $31 million (£25 million) seed funding round. The financing was led by Cambridge Innovation Capital (CIC) and SV Health Investors’ ...
Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research
24-Jul-2024
Lario Therapeutics, a biopharmaceutical company developing first-in-class precision medicines for epileptic and neurological disorders, announced it has been awarded a $6 million USD grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The programme is in collaboration with ...
Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases
01-Feb-2024
Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, announced their merger to form Calluna Pharma Inc. (Calluna). Calluna has raised EUR 75 million in a series A financing ...
Project leveraged Antiverse’s AI-driven Antibody Discovery Platform and GlobalBio’s ALTHEA semisynthetic libraries
17-Oct-2023
Antiverse Ltd, a biotechnology start-up company developing a computational antibody drug discovery platform, and GlobalBio, Inc., an antibody engineering company developing methods to engineer improved and more developable therapeutic antibodies, announced they will be extending their ...
The Company’s pipeline aims to address degenerative diseases of the eye, ear and pancreas via direct in vivo restoration of clinically valuable cell types
10-Oct-2023
Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced an additional $10 million USD closing of its Series A financing, bringing the total raised to $46 million USD in this round. The funding will support ...
"...a significant step forward in delivering on our vision to place benchtop gene synthesis into the hands of all researchers"
09-Oct-2023
EVONETIX LTD, the Company developing semiconductor scale technology to improve access to gene synthesis, announced its first placement of a DNA synthesis development platform for evaluation at Imperial College London. This is the Company’s first platform to be installed in an external scientific ...
NK:IO raises £1.2M, bringing total Seed funding to £5.1M
02-Aug-2023
NK:IO, a start-up company in natural killer (NK) cell biology applied to the development of exceptionally potent, off-the-shelf cell therapies targeting solid tumours, has raised £1.2M. This brings total equity financing to £3.2M and will enable the company to reach key milestones in progressing ...
Camena has also strengthened the Board of Directors with key appointments
11-Jul-2023
Camena Bioscience, a synthetic biology company providing genes to the pharmaceutical and biotechnology industries, announced it has closed a $10m Series A financing round, led by Mercia. The new funding will be used to scale operations and continue development of its pioneering DNA synthesis ...
New hope in the fight against unmet diseases
15-Dec-2022
PhoreMost Ltd., the UK-based biopharmaceutical company dedicated to ‘Drugging the Undruggable®’ disease targets, and ThinkCyte K.K, a biotechnology company pioneering novel cell analysis and sorting instruments, announced a strategic research partnership aimed at advancing modern phenotypic drug ...
